Needham Maintains Buy on Apellis Pharmaceuticals, Raises Price Target to $75
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reaffirmed a Buy rating on Apellis Pharmaceuticals (NASDAQ:APLS) and increased the price target from $70 to $75.
January 24, 2024 | 10:46 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Joseph Stringer maintains a Buy rating on Apellis Pharmaceuticals and raises the price target from $70 to $75.
The increase in price target by Needham suggests a positive outlook on Apellis Pharmaceuticals' stock, which could lead to increased investor confidence and a potential short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100